Corticosteroid therapy for nephrotic syndrome in children

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Hahn, Deirdre ^a   Hodson, Elisabeth M ^b   Willis, Narelle S ^c   Craig, Jonathan C ^c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; PREGNANE DERIVATIVE;

ADRENAL CORTEX INSUFFICIENCY; ADVERSE EVENT; CATARACT; CHILD; CORTICOSTEROID THERAPY; CUSHING DISEASE; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; EVIDENCE BASED MEDICINE; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERTENSION; INFECTION; MENTAL DISEASE; META ANALYSIS; NEPHROTIC SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL BIAS; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; DRUG ADMINISTRATION; INFANT; PRESCHOOL CHILD; RECURRENT DISEASE; RESPIRATORY TRACT INFECTIONS; SECONDARY PREVENTION; VIROLOGY; VIRUS DISEASES;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; INFANT; NEPHROTIC SYNDROME; PREDNISONE; PREGNENEDIONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESPIRATORY TRACT INFECTIONS; SECONDARY PREVENTION; VIRUS DISEASES;

EID: 84941289407     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001533.pub5     Document Type: Review

References (156)

1. Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Archives of Disease in Childhood 2008;93(3):226-8. [MEDLINE: 17573408]
2. Abeyagunawardena A, Thalgahagoda S, Illangasekera Y, Trompeter R. A short course of prednisolone during an upper respiratory tract infection reduces the risk of relapse in childhood nephrotic syndrome [abstract]. Pediatric Nephrology 2014;29(9):1689. [EMBASE: 71662409]
3. Abeyagunawardena AS, Thalgahagoda S, Illangasekera Y, Trompeter RS. Short course of daily prednisolone during upper respiratory tract infection reduces the risk of relapse in childhood nephrotic syndrome [abstract]. Archives of Disease in Childhood 2014;99:A155-6. [EMBASE: 71566356]
4. Anonymous. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbeitsgemeinschaft fur Padiatrische Nephrologie". European Journal of Pediatrics 1981;135(3):229-37. [MEDLINE: 7227377]
5. Anonymous. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft fur Padiatrische Nephrologie". Lancet 1979;1(8113):401-3. [MEDLINE: 84259]
6. Brodehl J, Krohn HP. Steroid trial in frequently relapsing nephrotic syndrome in children. Glomerulonephritis. International Conference on pathogenesis, pathology and treatment. New York: Wiley, 1977:210-5.
7. Anonymous. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet 1988;1(8582):380-3. [MEDLINE: 2893190]
8. Brodehl J, Krohn HP, Ehrich JH. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Klinische Padiatrie 1982;194(3):162-5. [MEDLINE: 6752557]
9. Ehrich JH. Initial treatment of idiopathic nephrotic syndrome: short vs standard prednisone [abstract]. 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:59. [CENTRAL: CN-00644361]
10. Ehrich JH for the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Short initial prednisone therapy versus standard prednisone therapy in the steroid responsive nephrotic syndrome [abstract]. Pediatric Nephrology 1987;1(1):C28. [CENTRAL: CN-00445202]
11. Ehrich JH, Arbeitsgemeinschaft fur Padiatrische Nephrologie. Minimal change nephrotic syndrome: long prednisone therapy vs standard prednisone therapy [abstract]. Nephrology Dialysis Transplantation 1991;6(10):771. [CENTRAL: CN-00260613]
12. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. European Journal of Pediatrics 1993;152(4):357-61. [MEDLINE: 8482290]
13. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Results of the nephrotic syndrome study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Pediatric Nephrology 1999;13:C26. [CENTRAL: CN-00636143]
14. Hoyer PF. Results of the nephrotic syndrome study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):104A. [CENTRAL: CN-00550522]
15. Hoyer PF for the Arbeitsgemeinschaft fur Padiatrische Nephrologie. The initial treatment of idiopathic nephrotic syndrome with prednisone and cyclosporin A: preliminary results of a therapeutic trial [abstract]. Pediatric Nephrology 1995;9(6):C91. [CENTRAL: CN-00401335]
16. Hoyer PF, Brodehl J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. Journal of the American Society of Nephrology 2006;17(4):1151-7. [MEDLINE: 16540560]
17. Bagga A, Hari P, Srivastava RN. Long (LP) versus standard (SP) initial prednisolone treatment for idiopathic nephrotic syndrome (NS) [abstract no: P225]. Pediatric Nephrology 1998;12:C155. [CENTRAL: CN-00583944]
18. Bagga A, Hari P, Srivastava RN. Long (LP) versus standard (SP) initial prednisolone treatment for nephrotic syndrome (NS) [abstract]. 3rd Congress. Nephrology Urology Transplantation Society (NUTS) of SAARC; 1999 Feb 18 - 21; Colombo, Sri Lanka. 1999:158. [CENTRAL: CN-00460325]
19. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatric Nephrology 1999;13(9):824-7. [MEDLINE: 10603129]
20. Broyer M, Terzi F, Gagnadoux MF, Guest G, Niaudet P. A randomized double blind study of deflazacort (D) versus prednisone (P) in the treatment of idiopathic nephrotic syndrome (INS) [abstract]. Journal of the American Society of Nephrology 1995;6(3):414. [CENTRAL: CN-00483349]
21. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatric Nephrology 1997;11(4):418-22. [MEDLINE: 9260237]
22. Bagga A, Ekka BK, Srivastava RN. Single versus divided dose prednisolone therapy for relapses of nephrotic syndrome (NS) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A113. [CENTRAL: CN-00261391]
23. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatric Nephrology 1997;11(5):597-9. [MEDLINE: 9323286]
24. Gulati A, Math A, Sreeniwas V, Hari P, Bagga A. Administration of daily corticosteroids prevents infection associated relapses in frequently relapsing nephrotic syndrome [abstract no: SU714]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
25. Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(1):63-9. [MEDLINE: 20847092]
26. Hiraoka M, Sudo M, West Japanese Cooperative Study of Kidney Disease in Children. Low versus standard dosage of prednisolone for initial treatment of idiopathic nephrotic syndrome in children [abstract no: A0445]. Journal of the American Society of Nephrology 1996;7(9):1335.
27. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Kidney International 2000;58(3):1247-52. [MEDLINE: 10972687]
28. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from intensive initial prednisolone therapy for nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):103A. [CENTRAL: CN-00550605]
29. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases 2003;41(6):1155-62. [MEDLINE: 12776266]
30. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. British Medical Journal Clinical Research Ed 1985;291(6505):1305-8. [MEDLINE: 3933645]
31. Anonymous. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children. Journal of Pediatrics 1979;95(2):239-43. [MEDLINE: 109598]
32. Jayantha UK. Comparison of ISKDC regime with a 7 months steroid regime in the first attack of nephrotic syndrome [abstract]. Pediatric Nephrology 2004;19:C81. [CENTRAL: CN-00583710]
33. Jayantha UK. Comparison of ISKDC regime with a six month steroid regime in the treatment of steroid sensitive nephrotic syndrome. Unpublished results 2002.
34. Jayantha UK. Comparison of ISKDC regime with a six month steroid regime in the treatment of steroid sensitive nephrotic syndrome [abstract no: FP2B]. 7th Asian Congress of Pediatric Nephrology; 2000 Nov 1-4; Singapore. 2000:28. [CENTRAL: CN-00583708]
35. Jayantha UK. Comparison of ISKDC regime with 6 month regime in patients with relapsing nephrotic syndrome. Unpublished results 2002.
36. Jayantha UK. Prolong versus standard steroid therapy for children with relapsing course of nephrotic syndrome [abstract no: P026]. Pediatric Nephrology 2004;19(9):C99. [MEDLINE: CN-00583706]
37. Kleinknecht C, Broyer M, Parchoux B, Loriat C, Nivet H, Palcoux JB, et al. Comparison of short and long treatment at onset of steroid sensitive nephrosis (SSN). Preliminary results of a multicenter controlled trial for the French Society of Pediatric Nephrology [abstract]. International Journal of Pediatric Nephrology 1982;3(1):45. [CENTRAL: CN-00550480]
38. Ksiazek J, Wyszynska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatrica 1995;84(8):889-93. [MEDLINE: 7488812]
39. Leisti S, Koskimies O, Perheentupa J, Vilska J, Hallman N. Idiopathic nephrotic syndrome: prevention of early relapse. British Medical Journal 1978;1(6117):892. [MEDLINE: 346147]
40. Li X, Li Z, Cheng Z. Treatment of children with simple nephrotic syndrom using prednison once per day. Acta Academiae Medicinae Hubei 1994;15(4):386-8. [EMBASE: 1995005617]
41. Liern M, Dieguez S, Canepa C. Recovery of total immunoglobulin and immunoglobulin subclasses in nephrotic syndrome: deflazacort vs methylprednisone [Recuperacion de la inmnoglobulina total y sus subclases en el sindrome nefrotico: deflazacort vs metilprednisona]. Nefrologia 2008;28(5):563. [MEDLINE: 18816222]
42. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron 2000;85(4):343-5. [MEDLINE: 10940745]
43. Mishra OP, Thakur N, Mishra RN, Prasad R. Prolonged versus standard prednisolone therapy for initial episode of idiopathic nephrotic syndrome. Journal of Nephrology 2012;25(3):394-400. [MEDLINE: 21928226]
44. Mocan H, Erduran E, Karaguzel G. High dose methylprednisolone therapy in nephrotic syndrome. Indian Journal of Pediatrics 1999;66(2):171-4. [MEDLINE: 10798055]
45. Mocan H, Mocan MZ, Erduran E, Karaguzel G, Aslan Y. The effect of high dose methylprednisolone therapy in patients with minimal change nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A74. [CENTRAL: CN-00261380]
46. Norero C, Delucchi A, Lagos E, Rosati P. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children [Cuadro inicial del sindrome nefrosico primario del nino: evaluacion a 18 meses de dos esquemas de tratamiento con prednisona. Groupo Cooperativo Chileno de Estudio del Sindrome Nefrosico del Nino]. Revista Medica de Chile 1996;124(5):567-72. [MEDLINE: 9035508]
47. Norero C, Delucchi A, Lagos E, Rosati P. Long term evaluation of two prednisone treatments in initial idiopathic nephrotic syndrome (INS) in children. Preliminary findings [abstract]. Pediatric Nephrology 1995;9(6):C88. [CENTRAL: CN-00550669]
48. Pecoraro C, Caropreso MR, Malgieri G, Ferretti A, Nuzzi F. Therapy of first episode steroid responsive nephrotic syndrome (FESRNS): a randomised controlled trial [abstract no: MP087]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v230. [CENTRAL: CN-00644161]
49. Pecoraro C, Caropreso MR, Malgieri G, Ferretti AVS, Raddi G, Piscitelli A, et al. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract no: OFC41]. Pediatric Nephrology 2004;19(9):C72. [CENTRAL: CN-00644160]
50. Pecoraro C, Caropreso MR, Passaro G, Ferretti AVS, Malgieri G. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):63. [CENTRAL: CN-00447140]
51. Satomura K, Yamaoka K, Shima M, Tanaka Y, Ashino N, Nakagawa K, et al. Standard vs low initial dose of prednisolone therapy for first episodes of nephrotic syndrome in children [abstract]. Pediatric Nephrology 2001;16(8):C117. [CENTRAL: CN-00447593]
52. Gulati S, Ahmed M, Sharma RK, Gupta A, Pokhariyal S. Comparison of abrupt withdrawal versus slow tapering regimen of prednisolone therapy in the management of first episode of steroid responsive childhood idiopathic nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A87. [CENTRAL: CN-00445595]
53. Sharma RK, Ahmed M, Gulati S, Gupta A, Pokhariyal S. Comparison of abrupt withdrawal versus slow tapering regimen of prednisolone therapy in the management of first episode of steroid responsive childhood idiopathic nephrotic syndrome. Unpublished results 2002.
54. Sharma RK, Ahmed M, Gupta A, Gulati S, Sharma AP. Comparison of abrupt withdrawal versus slow tapering regimens of prednisolone therapy in management of first episode of steroid responsive childhood idiopathic nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):97A. [CENTRAL: CN-00550434]
55. Bagga A, Sinha A, Saha A, Kumar M, Afzal K, Mehta A, et al. Randomized double blind, placebo controlled trial to compare the efficacy of 3-months versus 6-months therapy with prednisolone for the first episode of idiopathic nephrotic syndrome (CTRI/2010/091/001095) [abstract]. Pediatric Nephrology 2012;27(9):1707. [EMBASE: 71386357]
56. Sinha A, Bagga A, Sharma S, Saha A, Kumar M, Afzal K, et al. Randomized, double blind, placebo controlled trial to compare the efficacy of 3-months versus 6-months therapy with prednisolone for the first episode of idiopathic nephritic syndrome [abstract]. Pediatric Nephrology 2013;28(8):1361-2. [EMBASE: 71126981]
57. Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid- sensitive nephrotic syndrome. Kidney International 2014;87(1):217-24. [MEDLINE: 25029428]
58. Teeninga N, Kist-Van Holthe JE, Van Ruswuk N, De Mos NI, Hop WC, Wetzels JF, et al. Effect of extended prednisolone treatment from three to six months, with equal cumulative doses, on childhood nephrotic syndrome: a nation-wide randomised controlled trial [abstract]. Pediatric Nephrology 2012;27(9):1637-8. [EMBASE: 71386208]
59. Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. Journal of the American Society of Nephrology 2013;24(1):149-59. [MEDLINE: 23274956]
60. Teeninga N, Kist-van Holthe JE, van den Akker EL, Kersten MC, Boersma E, Krabbe HG, et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney International 2014;85(6):1444-53. [MEDLINE: 24429396]
61. Ueda N, Chihara M, Kawaguchi S, Niimomi Y, Nonada T, Matsumoto J, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. Journal of Pediatrics 1988;112(1):122-6. [MEDLINE: 3335948]
62. Takekoshi Y. Treatment of idiopathic nephrotic syndrome [abstract]. Pediatric Nephrology 1996;10(1):C3. [CENTRAL: CN-00402800]
63. Yoshikawa N, Ito H, Takehoshi Y, Honda M, Awazu M, Iijima K, et al. Standard versus long-term prednisolone with Sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Nippon Jinzon Gakkai Shi. Japanese Journal of Nephrology 1998;40(8):587-90. [MEDLINE: 9893457]
64. Yoshikawa N, Nakanishi K, Oba MS, Sako M, Ohashi Y, Iijima K. Increased duration and dose of prednisolone (PSL) treatment does not reduce relapses in childhood nephrotic syndrome [abstract no: SA-PO1080]. Journal of the American Society of Nephrology 2014;24(Abstracts):3B.
65. Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney International 2014;87(1):225-32. [MEDLINE: 25054775]
66. Zhang B, Liu T, Wang W, Zhang X, Fan S, Liu Z, et al. A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome. European Journal of Pediatrics 2014;173(4):509-15. [MEDLINE: 24240666]
67. Alatas H, Wirya IG, Tambunan T, Himawan S. Controlled trial of chlorambucil in frequently relapsing nephrotic syndrome in children (a preliminary report). Journal of the Medical Association of Thailand 1978;61 Suppl 1:222-8. [MEDLINE: 342654]
68. Anonymous. Nephrotic syndrome in children [Die nefrotiese sindroom by kinders]. South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde 1968;42(2):21-2. [MEDLINE: 5637304]
69. Anonymous. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. New England Journal of Medicine 1982;306(8):451-4. [MEDLINE: 7035953]
70. Brodehl J, Krohn HP, Ehrich JH. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Klinische Padiatrie 1982;194(3):162-5. [MEDLINE: 6752557]
71. Arun S, Bagga A, Bhatnagar S, Hari P, Menon S, Saini S. Efficacy of Zinc(Zn) in reducing relapses in steroid sensitive nephrotic syndrome (SSNS) double blind, randomized controlled trial (RCT) (CRG030600044) [abstract no: 184OP]. Pediatric Nephrology 2007;22(9):1481. [CENTRAL: CN-00724915]
72. Arun S, Bhatnagar S, Menon S, Saini S, Hari P, Bagga A. Efficacy of zinc supplements in reducing relapses in steroid-sensitive nephrotic syndrome. Pediatric Nephrology 2009;24(8):1583-6. [MEDLINE: 19347367]
73. Baluarte HJ, Hiner L, Gruskin AB. Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. Journal of Pediatrics 1978;92(2):295-8. [MEDLINE: 621612]
74. Anonymous. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991;337(8757):1555-7. [MEDLINE: 1675705]
75. Barratt TM, Soothill JF. A controlled trial of cyclophosphamide in steroid sensitive relapsing nephrotic syndrome of childhood [abstract]. Nephron 1971;8:95. [CENTRAL: CN-00253521]
76. Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 1970;2(7671):479-2. [MEDLINE: 4194935]
77. Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF. Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Archives of Disease in Childhood 1973;48(4):286-90. [MEDLINE: 4574639]
78. Barratt TM, Cameron JS, Chantler C, Counahan R, Ogg CS, Soothill JF. Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood. Archives of Disease in Childhood 1977;52(6):462-3. [MEDLINE: 879831]
79. Cerkauskiene R, Kaltenis P. Comparative study of prednisolone alone and prednisolone plus fusidic acid in the treatment of children with steroid-responsive nephrotic syndrome. Medicina (Kaunas, Lithuania) 2005;41 Suppl 1:26-30. [MEDLINE: 15901972]
80. Chiu J, McLaine PN, Drummond KN. A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood. Journal of Pediatrics 1973;82(4):607-13. [MEDLINE: 4698337]
81. Dayal U, Dayal AK, Shastry JC, Raghupathy P. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children [erratum appears in Nephron 1994;67(4):507]. Nephron 1994;66(4):408-12. [MEDLINE: 8015643]
82. Donia A, Ammar H, Moustafa F, Sobh M. Long-term efficacy of two unconventional adjunctive therapies in minimal change nephrotic children [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:37. [CENTRAL: CN-00509161]
83. Donia AF, Ammar HM, El Agroudy A, Moustafa F, Sobh MA. Long-term results of two unconventional agents in steroid-dependent nephrotic children. Pediatric Nephrology 2005;20(10):1420-5. [MEDLINE: 16047223]
84. Edefonti A, Ghio L, Bettinelli A, Paterlini G, Giani M, Nebbia G, et al. Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome. Contributions to Nephrology 1988;67:121-4. [MEDLINE: 3208520]
85. Edefonti A, Ghio L, Bettinelli G, Paterlini M, Giani G Nebbia A, et al. Unconjugated hyperbilirubinemia due to cyclosporin A (CYA) administration in children with nephrotic syndrome [abstract]. Pedatric Nephrology 1987;1(1):C8. [CENTRAL: CN-00465774]
86. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome (FR/SDNS): long term study [abstract]. Journal of the American Society of Nephrology 1992;3(3):310.
87. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome: long term study [abstract]. 9th Congress of the International Pediatric Nephrology Association; 1992 Aug 30-Sep 4; Jerusalem (Israel). 1992:C70. [CENTRAL: CN-00483820]
88. Ponticelli C. A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome. Journal of Nephrology 1989;2(2):147-51. [EMBASE: 1991014828]
89. Ponticelli C. Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract]. 10th Asian Colloquium in Nephrology; 1994 Dec 2-6; Karachi, Pakistan. 1994:116.
90. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrology Dialysis Transplantation 1993;8(12):1326-32. [MEDLINE: 8159300]
91. Ponticelli C, Rivolta E. Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis. American Journal of Nephrology 1990;10(Suppl 1):105-9. [MEDLINE: 2256469]
92. Grupe WE, Makker SP, Ingelfinger JR. Chlorambucil treatment of frequently relapsing nephrotic syndrome. New England Journal of Medicine 1976;295(14):746-9. [MEDLINE: 958261]
93. Hu GH, Dang XQ, Wang JH. Clinical effect of shenbing mistura combined with glucocorticoid on recurrent nephrotic syndrome in children and levels of interleukin-6 and tumor necrosis factor-alpha in blood and urine. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2006;26(10):892-5. [MEDLINE: 17121039]
94. Idczak-Nowicka E, Ksiazek J, Krynski J, Wyszynska T. Verification of indications for kidney biopsy in children with steroid-dependent nephrotic syndrome [Weryfikacja wskazan do biopsji nerki u dzieci ze sterydozaleznym zespolem nerczycowym]. Pediatria Polska 1996;71(8):679-83. [MEDLINE: 8927471]
95. Abramowicz M, Barnett HL, Edelmann CM Jr, Griefer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet 1970;1(7654):959-61. [MEDLINE: 4191931]
96. Arneil GC. International trial of azathioprine in nephrotic syndrome in childhood. Nephron 1971;8:95. [CENTRAL: CN-00253520]
97. Anonymous. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 1974;2(7878):423-7. [MEDLINE: 4137139]
98. Liu XY. Therapeutic effect of chai-ling-tang (sairei-to) on the steroid-dependent nephrotic syndrome in children. American Journal of Chinese Medicine 1995;23(3-4):255-60. [MEDLINE: 8571921]
99. Martinelli R, Pereira LJ, Silva OM, Okumura AS, Rocha H. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Brazilian Journal of Medical & Biological Research 2004;37(9):1365-72. [MEDLINE: 15334202]
100. McCrory WW, Shibuya M, Lu WH, Lewy JE. Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome. Journal of Pediatrics 1973;82(4):614-8. [MEDLINE: 4698338]
101. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatric Nephrology 1992;6(1):1-3. [MEDLINE: 1536727]
102. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatric Nephrology 2004;19(5):494-8. [MEDLINE: 15015070]
103. Rashid HU, Ahmed S, Fatima N, Khanam A. Levamisole in the treatment of steroid dependent or frequent relapsing nephrotic syndrome in children. Bangladesh Renal Journal 1996;15(1):6-8. [EMBASE: 1996266847]
104. Sharipov AM, Khamzaeva KA. Current aspects of transformation of morphological changes in children with nephrotic syndrome depending on the treatment regimen. Urologiia (Moscow, Russia) 2007, (2):68-71. [MEDLINE: 17580388]
105. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Archives of Disease in Childhood 1990;65(10):1147-59. [MEDLINE: 2248508]
106. Wang YP, Liu AM, Dai YW, Yang C, Tang HF. The treatment of relapsing primary nephrotic syndrome in children. Journal of Zhejiang University Science. B 2005;6(7):682-5. [MEDLINE: 15973773]
107. Weiss R. Results of a randomized, double-blind, placebo controlled, multi-center clinical trial of levamisole for the treatment of children with frequently relapsing or steroid dependent nephrotic syndrome. Personal communication 2005.
108. Weiss R, NY-NJ-Phila-Pediatric Nephrology Study Group. Randomized, double-blind, placebo (P) controlled trial of levamisole (L) for children (CH) with frequently relapsing/steroid dependant (FR/SD) nephrotic syndrome (NS) [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):289. [CENTRAL: CN-00520404]
109. Wingen AM, Muller-Wiefel DE, Scharer K. Comparison of different regimens of prednisone therapy in frequently relapsing nephrotic syndrome. Acta Paediatrica Scandinavica 1990;79(3):305-10. [MEDLINE: 2333744]
110. Yamashita F, Funatsu T, Nagayama K, Arihiro H, Anan S. Evaluation of alternate-day steroid therapy for nephrotic syndrome in childhood by cross-over study. Kurume Medical Journal 1971;18(3):153-60. [MEDLINE: 4944762]
111. Yang RY, Xu LF, Wang Q. The effect of Xuezhikang on lipid metabolism in patients with nephrotic syndrome. Hubei Yikedaxue Xuebao 2001;22(1):55-7.
112. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney International 2000;58(1):317-24. [MEDLINE: 10886577]
113. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. Placebo-controlled trial of mizoribine (MZR) in children with frequently relapsing nephrotic syndrome (FRNS). The Pediatric Mizoribine Study Group [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):163A.
114. Webb NJ, Frew E, Brettell EA, Milford DV, Bockenhauer D, Saleem MA, et al. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial. Trials 2014;15:147. [MEDLINE: 24767719]
115. Webb N, Trompeter R, Cummins C, Wheatley K, Frew E. Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double-blind trial. www.controlled-trials.com/ISRCTN16645249 (accessed 26 February 2015).
116. Arneil GC. The nephrotic syndrome. Pediatric Clinics of North America 1971;18(2):547-59. [MEDLINE: 4945403]
117. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatric Nephrology 1997;11(4):429-34. [MEDLINE: 9260239]
118. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney International 1999;55(5):1885-90. [MEDLINE: 10231451]
119. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629-39. [MEDLINE: 12944064]
120. Egger M, Dickersin K, Davey Smith G. Problems and limitations in conducting systematic reviews. In: Egger M, Davey Smith G, Altman D editor(s). Systematic Reviews in Health care: Meta-analysis in context. Second Edition. London: BMJ Publishing Group, 2001.
121. El Bakkali L, Rodrigues Pereira R, Kiuk DJ, Ket JC, van Wijk JA. Nephrotic syndrome in the Netherlands: a population-based cohort study and a review of the literature. Pediatric Nephrology 2011;26(8):1241-6. [MEDLINE: 21533870]
122. Elzouki AY, Amin F, Jaiswal OP. Primary nephrotic syndrome in Arab children. Archives of Disease in Childhood 1984;59(3):253-5. [MEDLINE: 6712274]
123. Gipson DS, Massengill SF, Yoa L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009;124(2):747-57. [MEDLINE: 19651590]
124. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International 2011;79(6):678-85. [MEDLINE: 21178977]
125. Greenbaum LA, Benndorf R, Smoyer WE. Childhood nephrotic syndrome--current and future therapies. Nature Reviews Nephrology 2012;8(8):445-58. [MEDLINE: 22688744]
126. Gulati A, Sharma AP, Sharma RK, Gupta A. Changing trends of histopathology in childhood nephrotic syndrome. American Journal of Kidney Diseases 1999;34(4):159-65. [MEDLINE: 10516344]
127. Haute Autorité de Santé. [Syndrome néphrotique idiopathique de l'enfant. Protocole national de diagnostic et de soinspour une maladie rare. 2008; 1-22]. www.has-sante.fr/portail/upload/docs/application/pdf/2008-06/pnds_sni_enfant.pdf (accessed 26 February 2015).
128. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
129. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
130. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analysis of randomized trials of health care interventions. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: ]
131. Hyams JS, Carey DE. Corticosteroids and growth. Journal of Pediatrics 1988;113(2):249-54. [MEDLINE: 3294360]
132. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatrics 2008;45(3):203-14. [MEDLINE: 18367765]
133. Anonymous. Minimal change nephrotic syndrome in children: deaths during the first 5-15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984;73(4):497-501. [MEDLINE: 6709428]
134. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatric Nephrology 2013;28(3):415-26. [MEDLINE: 23052651]
135. Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney International 2005;68(3):1275-81. [MEDLINE: 16105061]
136. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Archives of Disease in Childhood 1982;57(7):544-8. [MEDLINE: 7103547]
137. MacHardy N, Miles PV, Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatric Nephrology 2009;24(11):2193-201. [MEDLINE: 19672630]
138. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatric Nephrology 2001;16(12):1040-4. [MEDLINE: 11793096]
139. Mehls O, Hoyer PF. Dosing of glucocorticosteroids in nephrotic syndrome. Pediatric Nephrology 2011;26(12):2095-8. [MEDLINE: 21904778]
140. Mishra OM, Basu B, Upadhyay SK, Prasad R, Schaefer F. Behavioural abnormalities in children with nephrotic syndrome. Nephrology Dialysis Transplantation 2010;25(8):2537-41. [MEDLINE: 20200003]
141. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022]
142. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285(15):1992-5. [MEDLINE: 11308436]
143. Neuhaus TJ, Langlois V, Licht C. Behavioural abnormalities in children with nephrotic syndrome--an underappreciated complication of a standard treatment?. Nephrology Dialysis Transplantation 2010;25(8):2397-9. [MEDLINE: 20573807]
144. Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS. Ocular complications of paediatric patients with nephrotic syndrome. Clinical & Experimental Ophthalmology 2001;29(4):239-43. [MEDLINE: 11545423]
145. Niaudet P. Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(10):1457-8. [MEDLINE: 19808239]
146. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: ]
147. Rüth EM, Kemper M, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid sensitive nephrotic syndrome come of age: long-term outcome. Journal of Pediatrics 2005;147(2):202-7. [MEDLINE: 16126050]
148. Samuel S, Morgan CJ, Bitzan N, Mammen C, Dart AB, Manns BJ, et al. Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatric Nephrology 2013;29(12):2289-98. [MEDLINE: 23917450]
149. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387]
150. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatric Nephrology 1999;13(1):13-8. [MEDLINE: 10100283]
151. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. Journal of the American Society of Nephrology 1997;8(5):769-76. [MEDLINE: 9176846]
152. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Archives of Disease in Childhood 2000;83(1):45-51. [MEDLINE: 10868999]
153. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: ]
154. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: ]
155. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: ]
156. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: ]